# FDA recall D-0877-2023

> **Aurolife Pharma, LLC** · Class III · drug recall initiated 2023-05-18.

## Product

Glycopyrrolate Tablets, USP, 1 mg, 100-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01

## Reason for recall

Failed Impurities/Degradation Specifications

## Distribution

Nationwide within the United States

## Key facts

- **Recall number:** D-0877-2023
- **Recalling firm:** Aurolife Pharma, LLC
- **Classification:** Class III
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2023-05-18
- **Report date:** 2023-06-28
- **Termination date:** 2024-08-28

- **Voluntary/Mandated:** —
- **Location:** Dayton, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0877-2023

## Citation

> AI Analytics. FDA recall D-0877-2023. Retrieved 2026-07-15 from https://api.ai-analytics.org/recall/D-0877-2023. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*